{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:58:52Z","timestamp":1777327132557,"version":"3.51.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 38-year-old man with newly diagnosed multiple myeloma underwent <jats:sup>68<\/jats:sup>Ga-pentixafor PET\/CT for baseline assessment. <jats:sup>68<\/jats:sup>Ga-pentixafor PET\/CT demonstrated multiple focal bone and bone marrow lesions with intense radioactivity. After 9 cycles of chemotherapy against multiple myeloma, the patient experienced serologically complete remission of myeloma. Consistently, the follow-up <jats:sup>68<\/jats:sup>Ga-pentixafor PET\/CT for PET response showed significantly reduced uptake in the previously chemokine receptor 4\u2013positive bone lesions. However, intense and homogeneous uptake of <jats:sup>68<\/jats:sup>Ga-pentixafor was noted in the thymus with a smooth contour and slightly increased density, which is possibly caused by thymic hyperplasia after chemotherapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003375","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T20:01:21Z","timestamp":1605211281000},"page":"90-92","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma"],"prefix":"10.1097","volume":"46","author":[{"given":"Qingqing","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"68Ga-pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","year":"2015","journal-title":"Theranostics"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-pentixafor-PET\/MRI","volume":"9","year":"2019","journal-title":"Theranostics"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","article-title":"[68Ga]Ga-pentixafor PET\/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results","volume":"53","year":"2018","journal-title":"Invest Radiol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/RLU.0000000000002067","article-title":"Multiple myeloma presenting as a superscan on 68Ga-pentixafor PET\/CT","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/RLU.0000000000002131","article-title":"Chemokine receptor CXCR4-targeted PET\/CT with 68Ga-pentixafor shows superiority to 18F-FDG in a patient with Waldenstr\u00f6m macroglobulinemia","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13550-020-00681-7","article-title":"Preliminary evidence of imaging of chemokine receptor-4-targeted PET\/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG","volume":"10","year":"2020","journal-title":"EJNMMI Res"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/RLU.0000000000002258","article-title":"Chemokine receptor 4 expression in primary Sj\u00f6gren\u2019s syndrome","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/RLU.0000000000003004","article-title":"Pulmonary cryptococcosis accidentally detected by 68Ga-pentixafor PET\/CT in a patient with multiple myeloma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2967\/jnumed.117.193037","article-title":"Integrating MRI and chemokine receptor CXCR4-targeted PET for detection of leukocyte infiltration in complicated urinary tract infections after kidney transplantation","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.117.193854","article-title":"68Ga-pentixafor PET\/CT imaging of chemokine receptor CXCR4 in chronic infection of the bone: first insights","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2967\/jnumed.119.234484","article-title":"Imaging inflammation in atherosclerosis with CXCR4-directed 68Ga-pentixafor PET\/CT: correlation with 18F-FDG PET\/CT","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib15-20250621","first-page":"591","article-title":"Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy","volume":"42","year":"2001","journal-title":"J Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2967\/jnumed.108.058586","article-title":"Physiologic thymic uptake of 18F-FDG in children and young adults: a PET\/CT evaluation of incidence, patterns, and relationship to treatment","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1148\/rg.302095131","article-title":"Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls","volume":"30","year":"2010","journal-title":"Radiographics"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00003072-199610000-00004","article-title":"Normal thymic uptake of FDG on PET imaging","volume":"21","year":"1996","journal-title":"Clin Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1148\/radiology.163.1.3823458","article-title":"Benign thymic enlargement in adults after chemotherapy: CT demonstration","volume":"163","year":"1987","journal-title":"Radiology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:06:01Z","timestamp":1750539961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003375","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}